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Abstract
CORRELATION OF HOSPITAL PCI PROCESS MEASURES AND ASSOCIATION WITH
30-DAY RISK-STANDARDIZED OUTCOMES.
Philip W. Chui, Craig S. Parzynski and Jeptha P. Curtis. Center for Outcomes Research and
Evaluation, Yale University, New Haven, CT.
Over the past decade, there has been an explosion of interest in measuring and reporting
the quality of care delivered to patients undergoing percutaneous coronary intervention (PCI), with
the newest performance metrics just released in December 2013. One aspect of quality
measurement that remains poorly understood is the nature of the relationship between individual
PCI process measures as well as between process and outcomes measures such as risk-standardized
30-day mortality (RSMR) and readmission rates (RSRR). While process and outcomes measures
represent potentially important metrics of hospital quality, no study has examined whether these
two are measuring distinct or overlapping domains of hospital quality or whether there is an
association between the newly issued and previously existing set of process measures.
We performed a cross-sectional analysis using data from the National Cardiovascular Data
Registry’s (NCDR) CathPCI registry. We identified 1,219,544 patients across 1,331 catheterization
centers that had a procedure from January 1, 2010 to December 30, 2011. We utilized generalized
linear modeling to estimate hospital performance on individual and composite process measures
and generated pair-wide correlations between each set of process metrics. We also performed
correlation analyses to calculate the association between hospital performance on process metrics
and hospital performance on outcome metrics. We found strong correlations between medicationspecific process measures (p < 0.01), and the overall composite measure was significantly
correlated with most other process measures, particularly referral to cardiac rehab (p < 0.01).
Hospital performance on the new emerging process measures was lower than on existing ones, and
there was little correlation in hospital performance between these two sets. The composite measure
was correlated with hospital-specific 30-day RSRR for all patients and RSMR for NSTEMI patients
(p value < 0.05), but the association was modest, explaining at most 6.6% of the variation in
hospital-level outcome metrics. These results suggest that hospital-level performance on both
individual and composite PCI process measures explain only a small percentage of the hospital
variations in outcomes for PCI patients. Additional efforts are needed to better characterize how
hospitals can utilize these two perhaps distinct markers of quality to improve hospital performance.
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Introduction
Overview
An estimated 26.5 million or 11% of U.S. adults have coronary artery disease (CAD), and
CAD remains the most common cause of death at over 600,000 Americans per year. Around
715,000 myocardial infarctions happen on an annual basis with roughly four million hospital
admissions every year due to heart disease [1, 2]. Percutaneous coronary intervention (PCI) has
emerged within the past three decades as the preferred method in the U.S. to treat both stable
coronary artery disease and acute coronary syndromes. The prevalence of PCI has risen
dramatically within the past few decades: from 1987 to 2004, the number of PCI procedures rose
over 300%. Currently, PCI is one of the most commonly performed procedures in the U.S. with
over 650,000 patients undergoing PCI each year [3].
Given the rise in prevalence of PCI procedures, there has been a correspondent increase in
interest within the past decade in measuring and reporting the quality of care delivered to PCI
patients. Quality of care is commonly defined by performance on specific measures that have been
shown to reduce patient mortality or morbidity. Hospital performance on these metrics has been
made largely available by Medicare and other large health care organizations as a method to provide
patients, providers, and healthcare administrators objective markers of healthcare quality [4].
Several national organizations including the American College of Cardiology (ACC) and National
Quality Forum (NQF) have focused on developing and endorsing respectively, sets of PCI process
measures as benchmarks for hospital quality, with the most recent guidelines released within the
past three months [5].
However, there have been numerous studies in recent years that have shown that high
performance on process metrics does not lead to better patient outcomes as measured by 30-day
risk-standardized patient mortality and readmissions [6-7]. Despite improvements in hospital
performance on current PCI process metrics, there still remains a large variation in patient outcomes
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after PCI [8-9]. The significance of these process and outcome measures will continue to grow as
the performance on these metrics are becoming more readily available to patients and having
increasing financial consequences.
Despite an explosion of literature on PCI process and outcome measures, there remains
little understanding on the correlation of hospital performance on existing and emerging PCI
process measures as well as between individual process measures. Perhaps more importantly, from
a patient’s perspective, very little information exists on whether a hospital’s performance on PCI
process metrics is predictive of its performance on patient outcomes. Our study will be the first to
characterize the correlations among the existing and recently released PCI process metrics. Our
analyses will also describe the degree to which hospital performance on process measures can
explain hospital variations in PCI 30-day risk-standardized patient mortality and readmission rates.
Importance and definition of quality
As this thesis will focus heavily on the framework of quality and specifically PCI quality,
it is necessary to begin by providing a precise definition for “quality” in a healthcare setting. We
use the definition of quality established by the Institute of Medicine: “the degree to which health
services for individuals and populations increase the likelihood of desired health outcomes and are
consistent with current professional knowledge” [10]. A similar definition is in use by the U.S.
Agency for HealthCare Research and Quality (AHRQ), which states “quality health care means
doing the right thing at the right time in the right way for the right person and having the best results
possible” [11]. In a more practical context, one can define poor quality as too little care (e.g. “not
performing an indicated test”), too much care (e.g. “overprescribing medications that contain
significant side effects”), or the wrong care (e.g. “misdiagnosing complaints and performing
misguided procedures”).
It is well established that even though the United States vastly outspends any other country
in healthcare dollars as a gross product and per capita, the U.S. does not have superior outcomes in
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comparison to other industrialized countries [12]. In fact, the U.S. ranks among the lower third in
life expectancy at birth and the worst in a study of 19 countries on mortality from preventable
conditions including stroke, heart disease, and diabetes [13-14]. Specifically for PCI, despite the
U.S. having by far the highest revascularization rates by percentage and volume, our patient
outcomes are no better than many other developed countries [15]. As a result, within the last two
decades, there has been an increasing focus on the factors that affect the quality of patient care
administered throughout hospitals in the U.S. [16-17].
The emphasis on quality has not been limited to just academic literature. Hospitals
throughout the nation spend considerable resources to be included in media rankings, such as the
“Top American Hospitals” published by U.S. News every year [18]. Similarly, many websites are
now generating revenue by providing information to patients about different metrics of quality for
hospitals [19]. Both healthcare systems and the media are increasingly viewing patients as
consumers that have a wide variety of hospitals to choose from for their care, with many hospitals
now utilizing the topic of quality as a recruiting and marketing strategy to increase their patient
volume for financial incentives.
The U.S. government has also made significant advancements in the past two decades in
creating an infrastructure that allows for better public reporting of quality metrics and also
standardization of quality of care throughout hospitals in the U.S. Beginning in 2001, the Bush
administration in conjunction with Health and Human Services began a Hospital Quality Initiative
from which the current Hospital Compare database and website was designed. Hospital Compare
is a consumer-oriented website that allows patients to see how well hospitals provide recommended
and appropriate care to patients [4]. Since its inception, an increasing number of metrics and
outcomes have been available for patients to view. For instance, in 2005, the first set of “core”
metrics on heart failure, surgical care, acute myocardial infarction (AMI), and pneumonia were
added. Then, in 2008, Medicare data in addition to results from the Hospital Consumer Assessment
of Healthcare Providers and Systems (HCAHPS) survey became accessible, with the latter
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providing a systematic approach to capturing patients’ perceptions of their clinical care. Finally, in
the latter half of 2013, PCI outcomes including readmissions data became publically available on
Hospital Compare [4]. This focus on public reporting of quality metrics is not only on a national
level but also on a state-wide level with many states undergoing similar quality improvement
projects for their individual healthcare systems [20-21].
Theory of quality
From a conceptual standpoint, quality can be best understood by the Donabedian model
which is the most commonly accepted framework for understanding quality of care in a clinical
setting [22-24]. This model can be used as a foundation to understand the current concepts of
measuring PCI quality. The paradigm is separated into the three categories of structure, process,
and outcomes with structures affecting processes and processes affecting outcomes in a linear
fashion. Structural definitions of quality refer to the infrastructure of the healthcare system (e.g.,
are there enough hospital beds for a patient population). Process qualities refer to the clinical
interactions between a patient and doctor (e.g., with no other contraindication, was a PCI patient
with hyperlipidemia started on appropriate therapy). Outcomes refer to changes in patients’ overall
health status (e.g, did the patient experience any complications or was unnecessarily readmitted
after PCI) [22-24].
In this model, the unidirectional aspect of quality signifies that patient outcomes are a direct
consequence of high process quality which itself depends on sound structural healthcare
components [24]. For example, for an AMI patient, a facility must have the basic equipment and
personnel available for an interventional cardiologist to practice the level of care to reduce any
bleeding or other complications after the procedure. Although the structural components of the
model are the most identifiable, studies have shown that numerous structural qualities including
net profit, bed size, number of high-technology services offered, and teaching status have limited
effect on patient outcomes [25]. Moreover, as upgrading facilities can be a costly endeavor,
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financial constraints have also been a limiting barrier to change. On the other hand, many
researchers, including Donabedian himself, believe that the measurement of process quality is
nearly equivalent to the measurement of all healthcare quality as processes contain all acts of
healthcare (e.g. “diagnosing, treating, and preventing”) [22-23]. Hence, most of the focus
historically in quality improvement research has been on the processes aspect with the assumption
that given adequate resources, patient outcomes should be positive as a result of strong process
qualities. Researchers have generally preferred to study process measures over outcome metrics as
process metrics are a more discrete measure of clinical care and do not require the post-discharge
follow-up that outcome measures do. In particular, much attention has been placed on the aspect of
process quality termed technical process quality, which refers to whether the proper care was
administered skillfully and whether the correct choices were made in the diagnosis and treatment
of a patient [24]. The latter aspect (making the correct choices) generally can be assessed through
appropriateness and adherence to professional standards.
This conceptual background is crucial to our discussion of PCI quality. In an effort to
distinguish optimal medical systems that perform high PCI care, the emphasis on public reporting
of both appropriate usage and performance on specific PCI process metrics have skyrocketed within
the past decade. The rationale for this focus is simple: it enables patients and providers to have a
framework to characterize the quality of care delivered by PCI hospitals. Implicit in this effort is
the assumption that these measures will motivate providers and facilities to improve their
performance on these metrics. In accordance with the model above, the general supposition is that
performance on these process measures should and would lead to better PCI patient outcomes.
However, recent studies have shown a lack of association between performance on process measure
qualities and patient outcomes for AMI [6-7], although this relationship remains unknown for PCI.
Therefore, in light of the emphasis on public reporting of such process metrics, one large
component of our study is to better characterize the relationship between process qualities and
patient outcomes for PCI.
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Process measures and the emergence of outcome metrics
As we alluded to earlier in this introduction, past efforts to measure healthcare quality have
largely focused on process of care measures. The focus on process measures as opposed to outcome
measures (such as mortality rates) has been attributed to the challenges associated with measuring
outcomes. These challenges include low event rates, difficulty to risk-adjust for differences in case
mix, and difficulty in collecting post-discharge data [16-17]. Process measures, on the other hand,
are under better control by providers as most are for in-hospital patients, are simpler to benchmark,
require a shorter time-frame for assessment, and provide easier and clearer opportunities for
improvement [16-17, 26]. The main drawback to process measures is that one cannot create
measures for every service a hospital or clinician provides. Hence, process measures become
indicative of quality in two specific but indirect methods. The first is that because process measures
are generally evidence-based, they provide a direct indicator for whether the appropriate and
necessary care was provided to the patient. The implicit assumption is that proper performance of
a process measure will be linked to better patient outcomes because of correct, evidence-based
patient care. For instance, multiple randomized controlled trials have shown that beta-blockers
improve clinical outcomes for ST-elevation myocardial infarction (STEMI) patients through a
variety of different mechanisms [27]. If providers prescribe STEMI patients a beta-blocker
(provided they do not have a contraindication), then the pharmacological mechanisms of the
prescription medication will lead to better outcomes. The second mechanism that process measures
have historically been linked to quality is by serving as a quality indicator [23]. Using the same
analogy, if a hospital is diligent about providing all their appropriate STEMI patients with betablocker therapy then there is another implicit assumption that the hospital will also be diligent in
providing other proper services to ensure a patient has a rapid and safe discharge.
The fundamental importance of process measures has been recognized by both
governmental agencies and leading healthcare organizations. Centers for Medicare and Medicaid
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Services (CMS), the Joint Commission on Accreditation of Healthcare Organizations (JCHAO),
and NQF all endorse their own independent as well as joint process measures for common medical
conditions, such as acute myocardial infarction and congestive heart failure (CHF), as well as most
procedures including surgical operations [28-30]. For many of these process measures, there has
been a prompt response from the medical community to incorporate them into their clinical
practice, with many of the improvements driven by the public reporting of performance on these
metrics. For example, observational studies have shown that door-to-balloon (DTB) times of under
ninety minutes was linked to better patient outcomes for all-cause mortality [31]. DTB times less
than ninety minutes subsequently was adopted as a hospital process measure, and from 2005 to
2010, DTB times nationally decreased from a median time of 96 minutes to 64 minutes [32].
Recent evidence has suggested, however, that positive hospital performance in process
factors may not be correlated with outcome metrics such as risk-standardized mortality rates [6, 16,
33]. The most likely mechanism for this discrepancy is because process measures only capture a
small facet of factors that affect patient care, and other unmeasured quality-improving processes
can often play a significant role (e.g., nursing staff or social support) [34-35]. Furthermore, the
inclusion and exclusion criteria for a specific process metric may only allow a small minority of
patients to qualify for that condition [36]. While process measures convey important information
about the quality of healthcare delivered, there are associated opportunity costs of focusing on only
a small aspect of the healthcare delivery spectrum. Thus, there is growing concern that process
measures may not always be reliable indicators of outcome metrics, and recent literature has
focused on outcome metrics such as 30-day risk-standardized mortality rates (RSMR) and riskstandardized readmissions rates (RSRR) as separate but equally important markers of hospital and
clinical quality [37]. In other words, in reference to our previous example on STEMI patients and
beta-blockers, a hospital that performs well on prescribing beta-blockers to patients may not
necessarily have the appropriate axillary staff and services to ensure safe discharges of patients.
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Outcome measures have now been incorporated by CMS and other national organizations
such as JCAHO as a quality metric because they are thought to fairly account for the end result of
patient care and can provide a broad, holistic view of the care [38-39]. Using medical records as
validation, studies have also objectively established the use of outcome metrics such as 30-day riskadjusted mortality as a reliable marker for hospital performance [40]. It is worthy to note that
mortality has historically been the standard outcome metric; 30-day readmissions has also been
recently emphasized by Medicare as a quality measure that represents an adverse and often
preventable event for hospitals [41]. In addition, studies have shown that improvements in either
clinical treatment or behavioral intervention can result in a significant drop in readmissions,
resulting in substantial savings for society and protecting patients from unnecessary admissions
[42]. Because of the increasingly recognized importance of readmissions as an outcome measure,
Hospital Compare of CMS in 2009 began publicly reporting 30-day RSRR for AMI, CHF, and
pneumonia [43]. This information provides patients with data on hospital-level performance on
three common conditions that are often the focus of outcomes studies because they have been
shown to be some of the most frequent diagnoses that account for 30-day readmissions. From a
hospital perspective, Medicare has modified their payment scale to include readmissions as part of
the reimbursement scale, sparking a large national effort across all medical centers to institute
strategies to reduce readmissions for these conditions [41].
Therefore, in our study, when analyzing hospital quality we will include data on
performance of hospitals on both PCI process and outcome measures. In regards to the outcome
measures, we will be considering mortality and readmissions as separate outcomes. There are
several reasons for this distinction. A recent study has shown that hospital performance on 30-day
RSMR was not correlated with performance on 30-day RSRR for AMI and pneumonia and only
modestly associated in CHF [44]. The study emphasizes that 30-day RSRR and RSMR may be
qualifying two different aspects of hospital quality. Mortality rates can be indicative of the
systematic ability to provide early and efficacious interventions whereas readmission rates may
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symbolize hospital support on transitions of care, patient education, and discharge planning. Hence,
by incorporating both outcome metrics into our analyses, we can better discriminate between
different aspects of hospital-level services. Furthermore, we will focus our study on patients of
percutaneous coronary interventions because although it is a commonly performed procedure, it
has one of the highest rates of 30-day risk-standardized readmissions and only recently has had its
outcome metrics publically available [9].
PCI process and outcome metrics
Although PCI has emerged as a less invasive and potentially cost-effective procedure to
treat CAD in comparison to coronary artery bypass grafts (CABG), it remains a procedure with
substantial variation in quality [9]. A recent study has shown that even though PCI readmissions
are generally an unplanned event, approximately one in every seven Medicare beneficiaries will be
readmitted to a hospital within thirty days after a PCI procedure. There is also substantial variation
across hospitals in readmission rates, with one study calculating a range from 0-100% and the mean
(SD) at 15.5% (10.6%) [9]. This study further found that PCI readmissions are associated with a
higher level of all-cause 30-day mortality compared to those not readmitted (3.6% vs 0.6%), and
27.5% of patients readmitted received another revascularization procedure (PCI 25.8%, CABG
1.7%) [9]. The Medicare Payment Advisory Committee (MedPAC) noted that 10% of patients had
unplanned readmissions within two weeks after PCI and has estimated the cost of these
readmissions to our healthcare system to be 360 million dollars [45].
Many studies have tried to establish different variables to help explain the variance in PCI
outcomes. Some research has looked at peri-procedural decisions such as differences in bare-metal
or drug-eluting stents for saphenous vein grafts [46]. Other studies have examined clinical
presentations and demographic variables and their association with PCI outcomes. For instance,
one study found that gender was an independent predictor of PCI outcomes with women
experiencing higher all-cause mortality and complications after PCI [47]. A clinical study in 2002
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found that renal insufficiency was independently linked to cardiac events and mortality and a
similar finding was established for patients with diabetes [48-49]. Others have examined the role
of prescription medications before, during, and after PCI [50-52]. Finally, some researchers have
examined systematic contributions to PCI outcomes, most notably DTB times of less than ninety
minutes [31-32].
This entire set of research has generated a group of widely endorsed process measures that
include the following: therapy with aspirin, statins, and thienopyridines (P2Y12 inhibitors) in
patients with no contraindications at discharge, door-to-balloon time under ninety minutes, and
referral to cardiac rehabilitation for eligible patients. The ACC and NQF have also endorsed the
medication-specific criteria as process measures indicative of hospital performance [53]. The ACC
has supported the public reporting of these process measures and created the National
Cardiovascular Database Registry (NCDR) in 1998 with the intent to develop a standardized
national database that would allow for the characterization of PCI and cardiac catheterization
patients’ clinical profiles and outcomes [54]. NCDR has taken the lead in quality measurement and
has developed a portfolio of measures within the CathPCI Registry that includes not only the above
process measures but also more recently, outcomes metrics. The impact of public reporting has
given researchers and hospitals tangible goals to improve hospital performance on these metrics in
an effort to improve the quality of patient care [55-56].
The list of existing process measures was recently expanded in December 2013 to include
additional performance measures to highlight additional evidence-based practices that has emerged
in the past few years. In addition to the process measures described above, the new guidelines,
which are endorsed by the Physician Consortium for Performance Improvement (PCPI), American
Heart Association (AHA), Society for Cardiovascular Angiography and Interventions (SCAI), the
American Medication Association (AMA), ACC, and AQF, include the following: comprehensive
documentation of the indications for PCI, an appropriate reason for elective PCI, evaluation of the
individual’s ability to receive dual-antiplatelet therapy before the procedure, the use of embolic
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protection devices to treat saphenous vein bypass graft disease, documentation of the contrast dose
used in the procedure, participation in a regional or national PCI registry, the average annual
volume of PCIs performed by the physician over the past two years, and the average annual volume
of PCIs performed by a hospital over the past year [5]. The establishment of these new performance
measures is notable for several reasons. First, they are the first set of guidelines in the
cardiovascular literature to include appropriateness of usage as a specific metric. Second, they
consider the influence of pre-procedural, peri-procedural, and post-procedural factors that may
affect patient short-term and longitudinal outcomes. As these guidelines have just been released,
no study has examined hospital performance on these new measures or the correlation of hospital
performance between these new metrics and existing measures. Finally, while these new guidelines
are contributing to the growth of PCI quality assessment, little information is known about whether
hospital performance on these metrics are in fact predictive of hospital performance on patient
outcomes of PCI patients.
Hospital-level quality
One aspect of quality measurement that remains poorly understood is the nature of the
relationship between hospitals’ performance on PCI process measures and their performance on
outcomes measures such as 30-day mortality and readmissions. Both types of measures represent
potentially important assays of hospital quality, but it is unclear whether they are measuring
overlapping or distinct domains of hospital quality. On the one hand, existing PCI process measures
are evidence based and scientifically valid, and it would be reasonable to assume that observed
variation in these measures would be directly associated with variations in patient outcomes (for
example, a patient who was not discharged on appropriate antiplatelet therapy may be more likely
to be readmitted due to a thrombotic event). It would also be justifiable to assume that existing PCI
process measures can indirectly serve as a surrogate marker for the overall quality of care delivered
within the hospital. One example would be the proportion of patients referred for cardiac rehab; the
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rates of referral may not impact short-term risk of mortality and readmission but might be a marker
for the quality of the discharge process and the transition from the inpatient to the outpatient
settings.
On the other hand, there are reasons to believe that a hospital’s performance on core process
measures may not be associated with its performance on outcomes measures. Many of the process
measures are close to being topped out, with relatively little variation across process measures [57].
It is increasingly understood that although process measures remain evidence-based and clinically
important, they likely capture only a fraction of the multitude of factors that influence patient
outcomes. Chen and colleagues demonstrated recently that hospitals that performed well on
publically reported outcome measures for AMI, CHF, and pneumonia did not have better survival
rates for in-hospital cardiac arrest patients [58]. In contrast, Amarasingham and colleagues have
shown that hospitals that utilized electronic medical records were associated with fewer
complications, lower costs, and lower mortality rates [59]. Other studies have demonstrated that
more effective discharge planning can lead to significant drops in readmission rates [60]. Using
data from an Internet hospital survey, Bradley and colleagues recently showed that partnering with
community physician groups and local hospitals, arranging appropriate follow-up care before
discharge, and assigning nurses for medication reconciliation are all effective strategies a hospital
can use to lower its readmission rates [61]. None of these practices are included in the core process
measures. It is therefore becoming increasingly clear that numerous factors can play a role and be
markers for hospital quality. The focus of this thesis is to tackle the question of whether hospital
quality as assessed by its performance on existing and emerging PCI process metrics is associated
with 30-day hospital outcome measures such as 30-day mortality and readmissions rates.
Past studies have begun answering this question for acute myocardial infarction (AMI)
patients. For example, studies have noted that there is an inverse relationship between hospital
performance on core process metrics for AMI, CHF, and pneumonia and risk-adjusted mortality
rates for those three conditions [62]. Furthermore, Peterson and colleagues found a close
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association between in-hospital process measures and mortality of patients with acute coronary
syndromes. Their study showed that a rise in adherence to a composite process measure was
associated with an equivalent decline in in-hospital mortality [63]. In contrast, Bradley and
colleagues found that hospital performance was well correlated between process measures but
explained relatively little of the between hospital variation in 30-day mortality rates in patients with
AMI. Bradley and colleagues attributed the difference in their results to Peterson’s by noting that
their sample included patients that were transferred out, a group that is known to be healthier than
those who remain in one location [33]. Werner and Bradlow showed on a hospital-level that
hospital performance on core metrics for AMI, heart failure, and pneumonia was modestly
correlated with risk-adjusted mortality [6]. These same authors have found that variations in
mortality rates across hospitals are much larger than what would be expected from differences in
process measures performance [16]. Nevertheless, they have noted that recent efforts have been
made in hospitals to improve their performance on these core metrics and this has been associated
with an improvement in all outcome metrics though it is unknown if it is a casual link [55]. Other
studies have tried to identify high-performing hospitals to serve as models for quality improvement,
but many have noted that hospitals in the top quintile of one quality indicator are often in the bottom
quintile of another. In one particular study by Shwartz and colleagues, they analyzed over a
thousand hospitals on five measures—adherence to processes of care, 30-day readmission rates, inhospital mortality, patient satisfaction, and efficiency—and found very modest correlations
between them [26]. Therefore, there is ample evidence to suggest that for AMI patients, hospital
performance on core quality metrics is unfortunately only modestly correlated with performance
on outcome metrics.
However, there remains little information on patients specifically undergoing PCI; this
dearth of knowledge is particularly pertinent as PCI outcome metrics such as readmissions have
just been recently made publicly available. In one of the few available studies, Yeh and colleagues
examined data from Massachusetts and found that on a patient level, including evidence-based
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discharge medications did not substantially improve the discrimination of a model predicting an
individual patient’s risk of readmission [8].
Study objectives
Despite the current emphasis on PCI outcomes measures as a reflection of hospital quality
and the attention on hospital accordance with core process measures, there exists no study that has
determined the relationship between these two sets of quality metrics. It is crucial to underscore
that our paper will not be focusing on measuring the outcomes of the process metrics individually
(patient level) but rather together (hospital level) as a marker or surrogate of hospital quality. For
example, while other studies have answered whether variations in hospital outcome metrics can be
explained by patients receiving statins or aspirin upon discharge [50], our study will focus on
whether hospitals’ performance on the metric of prescribing aspirin upon discharge is associated
with that hospitals’ performance on various outcome metrics. Hence, our study will hopefully
establish whether hospital quality as determined by their performance on process metrics is an
overlapping or distinct domain from hospital quality defined by outcome metrics.
Developing a better understanding of the association between PCI process and outcomes
measures is important from several perspectives. With increasing public data about hospital
performance available to patients, it is important to elucidate whether hospital performance on core
PCI metrics can help patients locate hospitals that have the best outcomes. In other words, if a
patient was researching a catheterization site for his elective PCI, can a hospital’s performance on
clinical process measures be indicative of whether or not he would need to be readmitted or suffer
life-threatening complications after the procedure? Furthermore, understanding the association
between these two sets of quality metrics can help hospital administrators and policymakers target
their attention and resources to identifying quality care for one of the most commonly performed
procedures in the U.S. From an administrative standpoint, improved characterization of process
metrics can not only aid a hospital executive in understanding how his hospital is performing on
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the emerging PCI measures in comparison with existing ones but also demonstrate where efforts
and resources could best be utilized to improve patient outcomes. Furthermore, from a policy
standpoint, better understanding of this relationship between current process metrics and outcomes
can help direct what additional policies or process metrics are necessary to drive an improvement
in patient outcomes for PCI. If, as we hypothesize, these measures are only modestly correlated,
understanding the different factors that affect hospital performance on outcome metrics is crucial
for hospitals striving to improve their outcomes as well as patients looking to receive care with the
best outcomes.
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Specific Hypothesis and Aims
Specific hypothesis:
The overarching goals of this project are to a) examine the correlation among hospitals between
existing and emerging hospital process measures for patients undergoing percutaneous coronary
intervention (PCI) and b) to assess the degree to which hospitals’ performance on these process
measures are associated with the hospitals’ 30-day risk-standardized 30-day readmission rates
(RSRRs) and risk-standardized 30-day mortality rates (RSMRs) for patients undergoing PCI.
We hypothesize that existing and proposed PCI process measures are strongly correlated with one
another, but hospital performance on these measures will be only modestly correlated with PCI
outcomes measures.

Specific aims:
Aim 1: To examine the correlation between hospitals’ performance on existing NCDR-endorsed
PCI process measures and emerging PCI metrics
Aim 2: To determine the association between hospitals’ performance on PCI process measures for
patients undergoing PCI and risk standardized 30-day readmission rates
Aim 3: To determine the association between hospitals’ performance on PCI process metrics for
patients undergoing PCI and risk-standardized 30-day mortality rates for both ST-elevation
myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) patients
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Methods
Study design and population
We performed a cross-sectional analysis of all hospitals in the CathPCI registry that
reported at least 25 PCI procedures from January 1, 2010 to December 30, 2011. This time period
reflects the populations for whom information about both 30-day readmission and mortality rates
among Medicare beneficiaries is available using direct patient identifiers, including name, date of
birth, and social security numbers. Developed by the ACC in 1998, the CathPCI registry is the
oldest subset of the National Cardiovascular Data Registry (NCDR) and is the largest clinical
registry of elective and emergent PCIs in the world with representation of more than 1600 hospitals
and cardiac catheterization sites. The registry collects standardized data on patient demographics,
procedural, and clinical variables and peri-procedural and in-hospital outcomes [54]. The registry
also contains data metrics that provide information on national appropriate usage of PCI in various
hospitals [64]. The data completeness of the CathPCI registry is over 95%, and the data quality of
the registry has been extensively published in prior literature [65-66]. For this study, we used
version 4 of the CathPCI registry data collection form as it contains the elements necessary to
calculate appropriate usage and correlates with the time frame of our study sample.
No patients who underwent PCI in this time period were excluded from the analyses if they
had their procedure performed at a cardiac catheterization center with over 25 documented PCI
procedures within our study period. However, we did not consider information from subsequent
PCI procedures if more than one PCI procedure was performed during a single hospital stay.
This study was conceptualized by the first author of this manuscript and later designed
together by the first and senior author of this paper. This project was completed with the approval
of the CathPCI registry after a proposal submission to the registry written by the first and senior
author. These authors were also responsible for defining the variables and methodologies to the
statisticians who subsequently performed the statistical analyses in this manuscript. The authors of
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this paper then jointly completed the interpretation and analysis of the data. All of the data analyses
were performed and the study design formulated at the Center of Outcomes Research and
Evaluation at the Yale University School of Medicine. The Yale University Human Investigations
Committee approved analyses of this limited NCDR data set.
Process and Outcome Measures
Our first aim focused on hospital performance on current NCDR-endorsed and emerging
NCDR process measures for PCI. As mentioned previously, current NCDR-endorsed process
measures include aspirin at discharge, thienopyridines at discharge, statins at discharge, door-toballoon time under ninety minutes for patients presenting to the ED and door-to-balloon times
under one hundred twenty minutes for patients being transferred from another acute care facility,
and referral to cardiac rehabilitation after PCI. For emerging process measures recently approved
by the PCPI in December 2013, we were able to include the following using the data elements in
the registry: comprehensive indications for PCI, documentation for PCI appropriateness use criteria
(AUC), documentation of contrast dose, and use of embolic protection devices in saphenous vein
bypass grafts. Other recently approved metrics did not have the needed data variables in the registry
for us to calculate. These metrics included the following: pre-procedural renal assessment (GFR
calculation), pre-procedural evaluation for patient’s ability to tolerate and adhere to dual antiplatelet
therapy, documentation of radiation dose delivered during procedure, average annual volume of
PCIs performed by practicing physician over the past two years, and average annual volume of
PCIs performed by the hospital over the past calendar year.
For each of the process measures, we identified whether patients were eligible for each
individual metric and aggregated patient-level results to calculate the hospital performance in the
indicated performance measure. Measure-specific inclusion and exclusion criteria were applied to
each case to ensure that the population used to define performance was appropriate. For instance,
for the discharge medications, we excluded patients who were transferred or had a contraindication
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to the medication. For the door-to-balloon time under ninety minutes, we excluded patients who
were transferred from another institution because the upstream data before transfer was often not
captured in the registry. Furthermore, for the appropriate indications for PCI process measure, we
classified a procedure as indicated based on nationally established guidelines and algorithms that
were defined using registry variables [64]. The proportion of appropriate PCIs was calculated at
the hospital-level rather than on the individual patient-level which the rest of the process metrics
was calculated on. Hence, the proportion of appropriate PCIs was not calculated in the overall
composite measure.
We calculated hospital-specific risk standardized 30-day readmission and mortality rates
in a manner consistent with NQF-approved mortality and readmission measures. Specifically, there
are two models we used to calculate hospital risk-standardized 30-day mortality: one for patients
with STEMI or cardiogenic shock, and one for patients without STEMI and without cardiogenic
shock [67]. Both models use hierarchical logistic regression which takes into account clustering of
patients within hospitals. The models use various clinical characteristics of patients as adjustment
variables, allowing us to identify the independent effect of process measures on hospital-specific
mortality rates. Two models were used for RSMR because the different clinical features of the
patients amount to different adjustments being necessary. Both of the models have high
discrimination, and the c statistics for the STEMI and NSTEMI models are 0.83 and 0.82 [67]. The
model used for hospital-specific RSRR was developed in 2009 between researchers at Yale and the
CathPCI registry. This NQF-endorsed model has excellent correlation between expected and
observed readmissions (correlation coefficient r = 0.99) and good patient-level discrimination. The
c statistic for this model is 0.66 [68].
Statistical Analysis
We estimated performance for each hospital using a separate hierarchical generalized linear
model (HGLM) for each of our process measures. This method allowed us to estimate rates for
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hospitals that accounts for clustering of patients within hospitals and reflects the differences in
precision of estimates due to the varying numbers of patients treated at each hospital. Crude rates,
defined as the number of times a specific process measure was performed on a patient over the total
number of eligible patients at that hospital, were also calculated for all process measures.
Additional sensitivity analyses revealed that our HGLM estimated rates matched very well with
our crude rates.
For our first aim, we used the hospital performance estimates for each process measure to
calculate a set of pair-wise correlations. Because different numbers of patients have eligibility for
the process measures at each hospital, analyses was weighted by the total number of patients from
that hospital who were included in the calculation of the specific process measure. For each
correlation, we tested the null hypothesis that there is no correlation between measures, adjusting
p values for multiple comparisons. In addition, we calculated the Cronbach alpha coefficient for
the process measures and assessed the item-scale correlation for each measure. The Cronbach alpha
is an indicator of internal consistency and the item-scale correlation was used to measure the
correlation of the process measure with the rest of the scale if the original process metric is
removed.
We also created a composite measure that was defined as the total number of process
measures patients received over the total number of eligible performance measures for patients
treated at that hospital. This method is consistent with prior studies and allows for more variance
in hospital performance on core process metrics [33]. In secondary analyses, we restricted the
composite measure to only current process metrics (excluding emerging ones) as well as to only
medication-specific process measures (current NQF-endorsed ones). These composite measures
were also included in our linear modeling analyses and crude rate calculations.
For our second and third aims, we used correlation analyses to determine the association
of hospital risk-standardized 30-day mortality and readmission rates with corresponding hospital
composite score estimates of process measures. Again, we repeated our analyses with the composite
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measure restricted to only current process measures and then medication-specific metrics. We also
calculated correlation coefficients and the proportion of the hospital-specific variation in riskstandardized mortality rates explained as indicators of the strength of the associations. This
variation is the square of the correlation coefficient and is calculated out of 100.
We also performed several secondary analyses to assess the robustness of our primary
analyses. First, sensitivity analyses was performed that included hospital characteristics such as
geographical location, profit status, and teaching status. Second, we restricted the calculation of
hospital process measure performance to Medicare beneficiaries included in the calculation of
corresponding outcomes measures. Lastly, we repeated all analyses using crude process measures
rates instead of ones calculated from our linear models.
Analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC). All reported
p values are reported as 2-sided with significance at p < 0.05.
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Results
Sample descriptives
The total number of patients that was admitted during our study’s time period and satisfied our
methodological criteria was 1,219,544 patients with 1,268,860 PCI procedures with some patients
receiving more than one procedure over the course of several visits. These patients were distributed
over the 1,331 hospitals in the CathPCI registry that reported over 25 cases during our study period.
Hospital rates for each of the current NCDR-endorsed process measures, emerging process
measures, and composite measure in addition to 30-day RSMR (for STEMI patients), 30-day
RSMR (for non-STEMI patients), and 30-day RSRR are shown in Table 1.

Table 1: Hospital performance in 2010-2011 on current endorsed process measures, emerging process measures, and 30-day
mortality and readmission rates*

Variable

Aspirin at discharge
Thienopyridines at discharge
Statin at discharge
Proportion DTB time <90 minutes
Referral to cardiac rehab
Documentation of Contrast Dose
Use of embolic device

N

Mean

SD

25th percentile

Median

75th percentile

1288

96.8

3.6

96.0

97.9

99.0

1285

98.0

2.8

97.6

98.8

99.4

1288

89.8

7.2

86.8

91.4

94.7

1134

77.5

11.1

71.2

78.9

85.1

1291

53.8

35.1

18.4

60.7

87.2

1291

99.7

0.9

99.7

100.0

100.0

775

20.7

18.5

3.6

16.5

33.9

1156
62.5
16.8
51.1
64.3
Documentation of AUC eligibility
Proportion Of Appropriate PCIs
1156
29.2
16.8
17.5
26.3
Performed**
Overall Proportion Of Process
1291
85.2
7.6
78.5
86.4
Measures Met
Risk Standardized Readmission
1076
11.9
1.3
11.1
11.8
Rate
Risk-Standardized Mortality Rate
743
12.3
2.0
10.9
12.1
(STEMI)
Risk-Standardized Mortality Rate
1059
1.8
0.4
1.6
1.7
(NSTEMI)
* Hospitals were only considered eligible if they had more than 25 patients for each of the individual process measures
**Proportion of appropriate PCIs performed was not included in the overall proportion of process measures met

75.0
37.8
91.8
12.7
13.4
2.0
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Descriptive histograms for each of the individual process measures are given in the supplementary
materials section of the paper. Results from restricting the total composite measure to only the
current NCDR-endorsed process measures along with further restricting the composite measure to
only current medication process measures (aspirin at discharge, thienopyridines at discharge, and
statins at discharge) are shown in Table 2.

Table 2: Hospital performance in 2010-2011 based upon composite measure of NCDR-endorsed process measures and ACC/AHAendorsed process measures*

Variable

N

Mean

SD

25th percentile

Median

75th percentile

1291

83.8

9.9

74.6

85.8

92.6

1291

94.8

4.1

93.3

95.8

97.3

Overall proportion of total NCDRendorsed process measures met
Overall proportion of NCDRendorsed medication process
measures met
* Hospitals were only considered eligible if they had more than 25 patients for each of the individual process measures

Correlation of process measures
In analysis of the process measures correlations, we found moderate to strong correlations
(correlation coefficient > 0.40) across all the medications process measures, especially between
aspirin and thienopyridines at discharges, which was noted to have a very strong correlation
(correlation coefficient > 0.70). None of the medication process measures for medications were
correlated with that hospital having an average DTB time < 90. Referral to cardiac rehab was
significantly correlated with all other currently endorsed process measures (all correlation
coefficients > 0.10) and had a very strong correlation with the overall composite measure
(correlation coefficient > 0.90). Use of embolic devices was correlated with the medication process
measures and referral to cardiac rehab but not to timely reperfusion therapy (Table 3).
Documentation of AUC eligibility was strongly correlated with proportion of appropriate PCI’s
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performed (correlation coefficient > 0.60). The composite measure was significantly correlated to
all process measures except documentation of contrast dose and proportion of appropriate PCI’s
(correlation coefficient > 0.15).
If the overall composite measure was restricted to only approved process measures, the
composite measure was slightly weaker in correlation to all current process measures except for
referral to cardiac rehab where a stronger correlation was seen (Table 4). Further restricting the
overall composite measure as a marker of only the medication specific process measures yielded
no change in significance (Table 5).
Table 3:
Correlation coefficients for approved and emerging hospital process measures and 30-day risk-standardized readmission rates and
mortality rates* †
Aspirin
At
Discharge
Thienopyridines
at
Discharge
Statin at
Discharge

ThienoPyridines
At
Discharge

Statin At
Discharge

Proportion
DTB
Time <90
mins

Referral
To
Cardiac
Rehab

Documentation
Of Contrast
Dose

Use Of
Embolic
Device

Proportion
Of PCIs
AUC
Eligible

Proportion
Of
Appropriate
PCIs

Overall
Proportion
Of Process
Measures
Met

0.713
0.597

0.486

Proportion
DTB Time <90
mins

0.063

0.070

0.092

Referral To
Cardiac Rehab

0.194

0.139

0.181

0.111

Documentation
Of Contrast Dose

0.033

0.023

0.000

-0.002

0.019

Use Of Embolic
Device

0.247

0.182

0.215

-0.043

0.125

-0.046

Documentation
of AUC
0.078
0.014
0.154
0.084
0.022
0.048
0.041
eligibility
Proportion Of
Appropriate
-0.007
-0.072
0.022
0.101
-0.012
-0.005
-0.025
PCIs**
Overall
Proportion Of
0.392
0.304
0.415
0.159
0.951
0.037
0.199
Process
Measures Met
RiskStandardized
-0.120
-0.131
-0.139
-0.062
-0.100
0.007
-0.048
Readmission
Rate
RiskStandardized
-0.135
-0.153
-0.116
-0.069
-0.074
-0.003
-0.013
Mortality Rate
(STEMI)
RiskStandardized
-0.223
-0.143
-0.240
0.026
-0.063
0.009
-0.134
Mortality Rate
(NSTEMI)
* Hospitals with considered eligible only if they had more than 25 patients for each of the individual process measures
** Not included in overall composite measure
†
Weighted by number of eligible patients in each hospital
Red data points indicates significance (p < .01) after adjusting for multiple comparisons

0.650

0.178

0.078

-0.038

0.005

-0.132

-0.069

-0.075

-0.103

-0.010

0.009

-0.122
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Table 4:
Correlation coefficients for approved hospital process measures and 30-day risk-standardized readmission rates and mortality
rates* †
ThienoProportion
Aspirin
Overall Proportion
Pyridines
Statin At
DTB
Referral To
At
Of Process
At
Discharge
Time <90
Cardiac Rehab
Discharge
Measures Met
Discharge
mins
Overall Proportion Of
Process Measures
0.377
0.303
0.384
0.151
0.972
Met**
Risk-Standardized
Readmission Rate

-0.120

-0.131

-0.139

-0.062

-0.100

Risk-Standardized
Mortality Rate
-0.135
-0.153
-0.116
-0.069
-0.074
(STEMI)
Risk-Standardized
Mortality Rate
-0.223
-0.143
-0.240
0.026
-0.063
(NSTEMI)
* Hospitals with considered eligible only if they had more than 25 patients for each of the individual process measures
** Does not include emerging process measures
†
Weighted by number of eligible patients in each hospital
Red data points indicates significance (p < .01) after adjusting for multiple comparisons

-0.128
-0.103

-0.115

Table 5:
Correlation coefficients for hospital medication process measures and 30-day risk-standardized readmission rates and mortality
rates* †
Aspirin
Thienopyridines
Overall Proportion Of
Statin At Discharge
At Discharge
At Discharge
Process Measures Met
Overall Proportion Of Process
0.829
0.728
0.929
Measures Met**
Risk-Standardized Readmission
-0.120
-0.131
-0.139
-0.157
Rate
Risk-Standardized Mortality
-0.135
-0.153
-0.116
-0.146
Rate (STEMI)
Risk-Standardized Mortality
-0.223
-0.143
-0.240
-0.256
Rate (NSTEMI)
* Hospitals were considered eligible only if they had more than 25 patients for each of the individual process measures
** Only includes hospital medication process measures
†
Weighted by number of eligible patients in each hospital
Red data points indicates significance (p < .01) after adjusting for multiple comparisons

Item scale correlations (Table 6) for all of the process measures indicated only mediocre
internal consistency ranging from 0.01 (for documentation of contrast dosage) to 0.37 (for
aspirin at discharge). The raw Cronbach alpha ratio for all of the process metrics was 0.29.
Further restricting the item scale correlations to only approved process measures generated
a small range of correlations but no significant differences in raw values. In the approvedonly process metrics set, they ranged from 0.13 (for proportion DTB time < 90 minutes) to
0.31 (aspirin at discharge). The raw Cronbach alpha for this set was 0.21. Finally,
restricting the process measures to only medications (Table 8) yielded the strongest item
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correlations with ranges from statin at discharge at 0.59 to aspirin at discharge at 0.69. The
raw Cronbach alpha ratio for this data sample is 0.67.
Table 6:
Item-Scale Correlations for both approved and emerging process
measures
Variable
Aspirin at discharge
Thienopyridines at
Discharge
Statin at Discharge
Proportion DTB Time <90
mins
Referral To Cardiac Rehab
Documentation Of Contrast
Dose
Use Of Embolic Device
Documentation of AUC
eligibility

Table 7:
Item-Scale Correlations for all approved process measures*
Variable

N

Item-scale
correlation†

0.37

Aspirin at discharge

1288

0.31

1285

0.27

Thienopyridines at
Discharge

1285

0.26

1288

0.35

Statin at Discharge

1288

0.25

1134

0.10

Proportion DTB Time <90
mins

1134

0.13

1291

0.20
Referral To Cardiac Rehab

1291

0.21

N

Item-scale correlation†

1288

1291

0.01

775

0.17

1156

0.08

* Hospitals were considered eligible only if they had more than 25
patients for each of the individual process measures
† Item score correlation refers to the correlation of a specific item with
the remaining items in a set

Process measures and hospital-level specific
outcome measures
In the initial analysis with both current and
emerging process measures, the overall composite
measure was modestly but statistically significant with
hospital-specific RSRR (correlation coefficient > -

* Hospitals were considered eligible only if they had more than
25 patients for each of the individual process measures
† Item score correlation refers to the correlation of a specific
item with the remaining items in a set

Table 8:
Item-Scale Correlations for only medication process
measures*
Variable

N

Item-scale
correlation†

Aspirin at discharge

1288

0.31

Thienopyridines at
Discharge

1285

0.26

Statin at Discharge

1288

0.25

* Hospitals were considered eligible only if they had more
than 25 patients for each of the individual process
measures
† Item score correlation refers to the correlation of a
specific item with the remaining items in a set

0.132) and hospital-specific RSMR for NSTEMI patients (correlation coefficient > -0.122) but not
hospital-specific RSMR for STEMI patients (Table 3). The process measures of aspirin at discharge
and thienopyridines at discharge were both significantly correlated with hospital-specific RSRR,
RSMR for STEMI patients, and RSMR for NSTEMI patients (correlation coefficient range from 0.12 to -0.22). Statins at discharge was found to be correlated with hospital-level RSRR and RSMR
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for NSTEMI patients but not for STEMI patients. The percent variance for these process measures
and the overall composite was very modest ranging from 0.0% to 1.9% for the readmissions
outcome measure and 0.0% to 5.8% for 30-day mortality in STEMI and NSTEMI patients (Table
9).
Table 9:
Percent variance in hospital-level 30-day outcome measures for both approved and emerging process measures*
Variable

RSRR %

RSMR % (STEMI)

RSMR % (NSTEMI)

Aspirin at discharge

1.5

1.8

5.0

Thienopyridines at
Discharge

1.7

2.3

2.0

Statin at Discharge

1.9

1.3

5.8

Proportion DTB Time <90
mins

0.4

0.5

0.1

Referral To Cardiac Rehab

1.0

0.6

0.4

Documentation Of Contrast Dose

0.0

0.0

0.0

Use Of Embolic Device

0.2

0.0

1.8

Documentation of AUC eligibility

0.1

0.5

0.0

Proportion Of Appropriate PCIs

0.0

0.6

0.0

Overall Proportion Of Process Measures
Met

1.7

1.1

1.5

* Hospitals were considered eligible only if they had more than 25 patients for each of the individual process measures

There was no significant difference across the five quintiles of hospital performance on the
overall composite process measure in terms of hospital-level 30-day RSRR, RSMR for STEMI
patients, and RSMR for NSTEMI patients (Figure 1).

28
Figure 1: Box-whisker plots of risk-standardized 30-day all-cause readmission rates, mortality
rates for STEMI patients, and mortality rates for NSTEMI patients based on hospital performance
on an overall composite measure of current and emerging process measures by quintiles
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The overall composite measure was subsequently restricted to only current process
measures and there was again a modest but statistically significant correlation with hospital-specific
30-day RSRR (correlation coefficient > -0.128) and hospital-specific 30-day RSMR for NSTEMI
patients (correlation coefficient > -0.115) but not hospital-specific 30-day RSMR for STEMI
patients (Table 4). Further restricting the composite measure to only medication-specific process
measures resulted in a stronger and significant correlation across all three outcome variables with
the correlation coefficient ranging from -0.146 for hospital-specific 30-day RSMR to -0.256 for
hospital-specific RSMR for NSTEMI patients (Table 5). Although there was a slight increase in
the percent variance for the medication-specific composite measure (range from 2.1% to 6.7%),
both of the restricted composite measures only slightly explained the variation in hospital-level 30day risk standardized outcomes (Table 10).
Table 10:
Percent variance in hospital-level 30-day outcome measures for composite measure of only approved process measures and
medication-specific process measures*
Variable

RSRR %

RSMR % (STEMI)

RSMR % (NSTEMI)

Overall Proportion Of Process Measures
Met (Current process measures)

1.6

1.1

1.3

Overall Proportion Of Process Measures
Met (Medication-specific)

2.5

2.1

6.6

* Hospitals were considered eligible only if they had more than 25 patients for each of the individual process measures
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There was again only no significant differences across the five quintiles of hospital performance
on the overall composite measures, for current metrics and medication-specific metrics, in terms of
hospital-level 30-day RSRR, RSMR for STEMI patients, and RSMR for NSTEMI patients (Figure
2 and 3).
Figure 2: Box-whisker plots of risk-standardized 30-day all-cause readmission rates, mortality
rates for STEMI patients, and mortality rates for NSTEMI patients based on hospital performance
on an overall composite measure of current process measures by quintiles
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Figure 3: Box-whisker plots of risk-standardized 30-day all-cause readmission rates, mortality
rates for STEMI patients, and mortality rates for NSTEMI patients based on hospital performance
on an overall composite measure of medication-specific process measures by quintiles
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Sensitivity analyses
Secondary analyses showed that hospital characteristics were not independently associated
with any of the process measures or outcome measures. In restricting the calculation of hospital
process measures to only Medicare beneficiaries, we saw no changes in the corresponding outcome
measures. Secondary analyses also showed close agreement between crude process measure rates
and values from our linear models.
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Discussion
In a large cross-sectional analysis of PCI patients treated at 1620 hospitals, we have shown
that hospital performance on existing and emerging process measures is weakly correlated with
hospital performance on PCI outcome metrics, including hospitals’ 30-day risk-standardized
mortality and readmission rates. Although the composite process measure and several individual
performance metrics were found to be associated with short-term mortality and readmissions,
hospital performance on PCI-specific process metrics explained less than 10% of the variation in
mortality or readmission rates. We also found that with the exception of door-to-balloon times
under ninety minutes, there were strong correlations for hospital performance among the existing
process measures. However, existing process measures were less strongly correlated though for the
new emerging PCPI metrics recently released. These findings suggest that outcome metrics,
currently endorsed PCI metrics, and the emerging measures are each capturing complimentary but
not overlapping domains of quality.
At present, there is substantial variation across PCI hospitals in their 30-day riskstandardized mortality and readmission rates. Our crude all-cause mortality and readmission rates
are consistent with findings from prior studies [8-9, 67]. While previous analyses have examined
the association between AMI outcome metrics and AMI process measures and others have
identified specific clinical profiles and risk factors of PCI patients that correlate to mortality or
readmission rates, our study was the first to examine the relationship between hospital-performance
on PCI process measures and PCI outcome measures [8, 33].
Our analyses revealed that the composite measure was statistically significantly correlated
to both hospital-level 30-day RSRR, and RSMR for patients without STEMI and without
cardiogenic shock. However, the strengths of the correlation was modest. Furthermore, there was
no correlation between the composite process measure and for RSMR for STEMI patients. This
finding was similar when we restricted the composite measure include only the currently approved
process metrics. When we further restricted the composite measure to discharge medications, all
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three outcome variables were significantly correlated. We also noted that the inclusion of the
emerging process measures into the composite did not result in any significant change in the percent
variance explained by the outcome measures. Our results suggest that similar to the existing process
measures, the newly approved ones capture an aspect of quality that is separate and distinct from
that reflected by outcome measures.
There are several possible reasons why even with the addition of new process measures,
the percent variance explained of the outcome metrics is still very modest. First, many of the
process measures such as statin at discharge or documentation of contrast dose are close to having
a performance measure performance of 100% [33]. This finding may therefore limit the ability to
discriminate hospitals on these measures. Furthermore, as discussed previously, hospitals’
outcomes are influenced by many variables not captured in process measures. These include the
quality of medication reconciliation, adherence to patient safety guidelines, nurse staffing levels,
and availability of post-hospitalization home healthcare services [61, 69]. Similarly, process
measures do not capture the quality of the transition of care from inpatient to the outpatient setting,
or the effectiveness of communication with primary care providers, both of which may represent
key determinants of patient outcomes [36, 65]. Many of these practices represent strategies that
require collaboration beyond the walls of a hospital and effective, efficient communication between
hospitals, patients, and providers. Thus, there is ample research now to suggest that to improve
outcomes, hospitals will have to take ownership and ensure the quality not only of care within its
facilities, but also direct social services and transitions of care that may involve family and
community contributions [8, 70].
While the new PCPI performance metrics are groundbreaking in attempting to establish
guidelines for appropriateness as well as markers for technical expertise, our findings suggest that
these new measures continue to encapsulate only a specific and narrow domain of quality. We
believe that additional sets of process measures may be needed for PCI in the future to capture a
more complete picture of the services that a hospital provides, which may extend beyond the sphere
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of direct clinical care. Alternatively, we appreciate that outcome measures continue to capture
quality that represents all aspects of care that may be impossible to reflect in just process measures.
While additional efforts to create standardized performance metrics in areas such as the transition
of care, post-discharge follow-up, or behavioral modification may align with current efforts to
improve overall all-cause patient outcomes, the difficulty of creating such performance measures
may suggest a complimentary and important role that outcome measures play in representing
quality.
Although our results do seemingly undermine the significance of process measures as a
quality indicator, it is crucial to emphasize that in fact we are suggesting there are numerous
advantages to public reporting of process measure performance. Public reporting of these measures
can provide an actionable item for hospitals to achieve with the hope of affecting long-term
outcomes for patients. Furthermore, it can provide to patients a marker of the clinical care they may
receive at an institution and a source of motivation for hospitals. In addition, improvements in
clinical care has been linked to public reporting and the emphasis on process measures [71].
However, as many previous researchers have noted, there is a need for additional research to
identify process measures that can better explain the variations in outcome metrics [33, 72].
Defining such variables or performance metrics though may not be possible in many cases.
Selecting process measures must satisfy the basic principle that the process measure is clinically
meaningful, can be adjusted for patient variability, be valid and reliable, can be modified by
improvements in the care delivery, and can measure the performance of healthcare providers [72].
In many cases such as the transition of care of patients, the heterogeneity of each case currently
prohibits the use of standardized process measures as a quality marker. If such process measures
were to be developed, then identification and implementation of these process measures can
establish, a tangible link between patient end outcomes and evidence-based clinical care. Until the
establishment of those process measures, however, outcome metrics provide an indirect but
encompassing manner to capture quality of care in the various avenues of healthcare delivery.
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Our study is also the first to identify pair-wise correlations for PCI-specific existing
performance metrics. Similar to past studies of AMI patients, the medication-specific process
measures had the highest-level of correlation with one other [33, 63]. When we restricted the itemscale correlations to only the three medication process measures, a much higher correlation was
seen in comparison to analyses where we included all process metrics. This finding is consistent
with other studies that showed medication-specific measures have a high level of internal
consistency with one another [33]. Our results also indicate that hospital performance of having a
DTB time less than ninety minutes was only significantly correlated with referral to cardiac rehab.
This dissociation of DTB times from other process measures has been documented in literature
[73]. Improvements in DTB time require a systematic shift in hospital procedures and structure that
may often involve changes in how patients are triaged and transferred, assignment of new hospital
floor space with the capability to quickly receive AMI patients, and designating and training the
proper personnel.
Our results showed that hospital performance on referral to cardiac rehabilitation was
significantly correlated with all other existing NCDR-approved measures except proportion of
DTB times < 90 minutes. A robust correlation was seen between referral to cardiac rehabilitation
and the overall composite measure comprising of both current and emerging process measures and
discharge medications metrics. There may be several reasons for this strong correlation. As
mentioned above, most of the process measures have been topped and hence very little variation
exists in the top two to three quintiles of hospital performance [6, 33]. For instance, our crude rates
show that the median to 75th percentile for hospital performance on aspirin and thienopyridines at
discharge are 97.9%-99.0% and 98.8%-99.4% respectively. These numbers suggest that hospitals
and providers are performing identically well in their clinical practices to generate the high
performance marks on these process measures; the lack of variation in these metrics do not provide
much statistical discrimination when combined with the overall composite measures [16]. In
contrast, hospital performance for referral to cardiac rehabilitation has a mean performance of
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around 50% generating significantly more variation that likely contributed to the strong correlation
seen with the overall composite measure. The rather low crude values for hospital performance for
referral to cardiac rehab are consistent with ranges found in the literature that suggest that this
specific process measure represents an area for improvement for hospital performance [74].
We found in our analyses that any variation in the overall composite measure was largely
driven by referral to cardiac rehabilitation, given the very robust correlation between these two
metrics. Several composite measures already exist in NQF’s portfolio of endorsed measures for
other areas of focus such as AMI and CHF. With an increasing number of performance metrics
available to the public, NQF has considered composite measures as a mechanism to provide a valid
and comprehensive picture of healthcare quality that single individual process measures cannot
capture [75]. Our findings, however, suggest that a composite measure for PCI currently would be
superfluous given that it would be driven largely by one individual metric.
Focusing on emerging metrics, the mean hospital performance was actually higher in the
composite measure comprising of both currently approved and emerging metrics as opposed to the
composite measure of just the existing measures. However, few of the emerging metrics were
significantly correlated with the core measures with the exception of use of embolic protection
devices. The results therefore indicate that hospitals are already performing well on the emerging
metrics though overall performance on the current metrics is not associated with performance on
the new measures. This lack of correlation between the emerging and existing metrics suggests that
the emerging metrics are representative of another dimension of quality that the previous metrics
was not capturing, albeit one in which there is already relatively little opportunity to improve. It is
very likely that as these new recommendations become fully incorporated into hospital guidelines,
the association between the current and emerging set of process measures will become stronger in
the upcoming years.

.

There are several limitations to our study that should be considered. The first one is that
our entire patient population is from a single registry. We appreciate that these results may not be
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generalizable to all PCI centers in the U.S. However, given the CathPCI registry captures over 95%
of PCI procedures performed in the US, we do believe our data sample is fairly inclusive of all
patient and hospital demographics and relatively free from selection biases [54]. In addition, given
the restraints of the available data elements in the registry, we were not able to fully capture all of
the emerging and newly PCPI approved process measures. Some of these metrics such as the
average volume of patients seen by a provider or hospital may represent more systematic aspects
of quality that is more represented in outcome metrics. While our results should provide a fairly
accurate snapshot of hospital performance on these new metrics, it is possible that the performance
on the individual metrics we studied in this analyses are not representative of hospital performance
as a whole on the full portfolio of novel metrics. Furthermore, it is possible that a composite
measure incorporating more of the emerging metrics may be stronger in explaining hospital-level
variance in 30-day outcome measures. There are also inherent limitations associated with crosssectional analyses. As with all observational studies, it is impossible to establish causation between
our two sets of quality metrics. It is possible that hospital or patient characteristics could have
served as cofounders although hospital size was weighted in our logistical regressions. Lastly, as
we addressed earlier in this discussion, although the composite measure has been used in prior
studies as a fair metric to judge a hospital’s performance overall on process measures [33, 76],
specific performance measures such as referral to cardiac rehabilitation can be a disproportional
contributor to the discriminative ability of the composite measure.
In summary, hospital performance on current and emerging PCI-metrics only explain a
small variation of hospital performance on outcome measures such as 30-day risk-standardized
mortality and readmission rates. This fact highlights that these two sets of markers are capturing
distinct components and aspects of hospital quality care. From a perspective of a PCI patient, both
sets of quality metrics should be considered together in evaluating hospital quality. Additional
efforts are needed to better how characterize how hospitals can utilize these two distinct markers
of quality to improve hospital performance.
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Figure 2: Histogram distribution for the process measure of aspirin at discharge
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Figure 3: Histogram distribution for the process measure of thienopyridines at discharge
Thienopyridine at Discharge
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Figure 4: Histogram distribution for the process measure of statins at discharge
Statin at Discharge
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Figure 5: Histogram distribution for the process measure of proportion of DTB times < 90 mins
Appropriate DTB Time
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Figure 6: Histogram distribution for the process measure of referral to cardiac rehab
Referral to Cardiac Lab
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Figure 7: Histogram distribution the process measure of documentation of contrast dosage
Documentation of Contrast Dose
1200

1000

Min

86.52

1st %

95.71

5th %

98.30

25th %

99.74

Median
75th %

100.0
100.0

95th %

100.0

99th %

100.0

Max

100.0

Count

800

600

400

200

0
86.4

87.2

88.0

88.8

89.6

90.4

91.2

92.0

92.8

93.6

94.4

95.2

96.0

96.8

97.6

98.4

99.2

100.0

% of Process Measure Met

Figure 8: Histogram distribution for the process measure of use of an embolic protection device
Use of an Embolic Protection Device
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Figure 9: Histogram distribution of proportion of PCIs considered AUC eligible
Proportion of PCIs AUC Eligible
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Figure 10: Histogram distribution of proportions of PCIs consider appropriate
Proportion of PCIs Considered Appropriate
250

200

Min

0.00

1st %

4.44

5th %

8.32

25th %

17.46

Median
75th %

26.35
37.82

95th %

62.90

99th %

84.21

Max

96.08

Count

150

100

50

0
0

6

12

18

24

30

36

42

48

54

% of Process Measure Met

60

66

72

78

84

90

96

50
Figure 10: Histogram distribution of overall proportion of process measures met
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